

## Basic Study

**Overexpression of fibrinogen-like protein 2 protects against T cell-induced colitis**

Agata Bartczak, Jianhua Zhang, Oyedele Adeyi, Achiya Amir, David Grant, Reginald Gorczynski, Nazia Selzner, Andrzej Chruscinski, Gary A Levy

Agata Bartczak, Jianhua Zhang, David Grant, Reginald Gorczynski, Nazia Selzner, Andrzej Chruscinski, Gary A Levy, Multi Organ Transplant Program, University Health Network, Toronto, Ontario M5G 2C4, Canada

Oyedele Adeyi, Department of Laboratory Medicine and Pathology, University Health Network, Toronto, Ontario M5G 2C4, Canada

Achiya Amir, Gastroenterology, Hepatology and Nutrition Division, The Hospital for Sick Children, Toronto, Ontario M5G 1X8, Canada

**Author contributions:** Chruscinski A and Levy GA are co-senior authors; Bartczak A, Gorczynski R, Selzner N, Chruscinski A, and Levy GA conceived and designed the experiments; Bartczak A, Zhang J, Adeyi O and Amir A performed the experiments; Bartczak A, Adeyi O, Chruscinski A and Levy GA analyzed the data; Bartczak A, Grant D, Selzner N, Chruscinski A and Levy GA wrote the paper.

**Supported by** the Heart and Stroke Foundation of Canada, No. G-13-0002851; the Canadian Institutes of Health Research Training Program in Regenerative Medicine to Bartczak A and Chruscinski A; and the Ontario Graduate Scholarship in Science and Technology to Bartczak A.

**Institutional animal care and use committee statement:** All procedures involving animals were reviewed and approved by the Animal Care Committee of University Health Network (AUP No. 903.19).

**Conflict-of-interest statement:** The authors declare no conflict of interest.

**Data sharing statement:** No additional data are available.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on

different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Invited manuscript

**Correspondence to:** Dr. Gary A Levy, Professor, Multi Organ Transplant Program, University Health Network, 585 University Avenue, PMB 11-182, Toronto, Ontario M5G 2N2, Canada. [gary.levy@uhn.ca](mailto:gary.levy@uhn.ca)  
Telephone: +1-416-3405166  
Fax: +1-416-3403378

**Received:** December 29, 2016

**Peer-review started:** December 30, 2014

**First decision:** January 19, 2017

**Revised:** February 13, 2017

**Accepted:** March 15, 2017

**Article in press:** March 15, 2017

**Published online:** April 21, 2017

## Abstract

### AIM

To determine the effect of overexpression of fibrinogen-like protein 2 (FGL2) on regulatory T cell (Treg) and effector T (Teff) cell function on T cell-induced colitis in *Rag1<sup>-/-</sup>* mice.

### METHODS

Treg and Teff cells from *fgl2<sup>-/-</sup>*, *fgl2<sup>+/+</sup>*, and *fgl2<sup>Tg</sup>* mice were purified by FACS. They were studied *in vitro* for immunosuppressive activity and cell proliferation and *in vivo* for their effects on the development and prevention of T cell-induced colitis in *Rag1<sup>-/-</sup>* mice.

### RESULTS

*In vitro*, *fgl2<sup>Tg</sup>* Treg had enhanced immunosuppressive activity, and *fgl2<sup>Tg</sup>* Teff had reduced proliferation to

alloantigen stimulation. Transfer of Teff from C57Bl/6J mice (*fgl2<sup>+/+</sup>*) into *Rag1<sup>-/-</sup>* mice produced both clinical and histologic colitis with dense infiltrates of CD3<sup>+</sup> T cells, crypt abscesses and loss of goblet cells. *Fgl2<sup>Tg</sup>* Treg prevented the development of T cell-induced colitis, whereas *fgl2<sup>+/+</sup>* and *fgl2<sup>-/-</sup>* Treg were only partially protective. In mice that received *fgl2<sup>Tg</sup>* Treg, the ratio of Foxp3<sup>+</sup> to CD3<sup>+</sup> cells was increased both in the colon and in mesenteric lymph nodes, and Teff cell proliferation as determined by staining with Ki67 was reduced. Teff cells from *fgl2<sup>Tg</sup>* mice did not produce colitis.

### CONCLUSION

Here we show that *fgl2<sup>Tg</sup>* Teff are hypoproliferative and do not induce colitis. We further demonstrate that *fgl2<sup>Tg</sup>* Treg prevent colitis in contrast to *fgl2<sup>+/+</sup>* Treg, which were only partially protective. These studies collectively provide a rationale for exploring the use of FGL2 or Treg expressing high levels of FGL2 in the treatment of inflammatory bowel disease.

**Key words:** Fibrinogen-like protein 2; Colitis; Regulatory T cells; Transgenic mouse; Inflammatory bowel disease

© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** This study investigates the effect of over-expression of fibrinogen-like protein 2 (FGL2) on T cell-induced colitis in mice. For these experiments, effector T cells (Teff) and regulatory T cells (Treg) were isolated from a newly generated line of transgenic mice that ubiquitously overexpress FGL2 (*fgl2<sup>Tg</sup>*). Following injection in *Rag1<sup>-/-</sup>* mice, *fgl2<sup>Tg</sup>* Treg were present in high numbers in mesenteric lymph nodes and were superior to *fgl2<sup>+/+</sup>* Treg in preventing T cell-induced colitis. *Fgl2<sup>Tg</sup>* Teff were not capable of inducing colitis. This work is important in showing that the immunoregulatory molecule FGL2 may be useful in the treatment of colitis.

Bartczak A, Zhang J, Adeyi O, Amir A, Grant D, Gorczynski R, Selzner N, Chruscinski A, Levy GA. Overexpression of fibrinogen-like protein 2 protects against T cell-induced colitis. *World J Gastroenterol* 2017; 23(15): 2673-2684 Available from: URL: <http://www.wjgnet.com/1007-9327/full/v23/i15/2673.htm> DOI: <http://dx.doi.org/10.3748/wjg.v23.i15.2673>

### INTRODUCTION

Inflammatory bowel disease (IBD) consists of a group of chronic relapsing inflammatory diseases of the gastrointestinal tract including Crohn's disease (CD) and ulcerative colitis<sup>[1]</sup>. The onset of colitis is dependent on dysregulated innate and adaptive immune responses to bacterial flora<sup>[1-5]</sup>. A well-characterized model of IBD caused by infusion of CD4<sup>+</sup>CD25<sup>+</sup>CD45RB<sup>high</sup> effector T

cells (Teff) into immunodeficient *Rag1<sup>-/-</sup>* mice has been used to study the pathogenesis of IBD<sup>[2,4,5]</sup>. Infusion of Teff cells into *Rag1<sup>-/-</sup>* mice leads to the development of colitis<sup>[5]</sup>. Infusion of CD4<sup>+</sup>CD25<sup>+</sup>CD45RB<sup>low</sup> regulatory T cells (Treg) has been reported to be protective against the development of T-cell induced colitis<sup>[6,7]</sup>. It is now known that Treg are a subset of CD4<sup>+</sup> T cells that are characterized by the expression of the transcription factor Foxp3<sup>[8]</sup>. Foxp3<sup>+</sup> Treg are important in regulating host immune responses to pathogens and maintaining tolerance<sup>[9]</sup>. Foxp3<sup>+</sup> Treg are comprised of functionally diverse subsets with distinct phenotypes and functions<sup>[10]</sup>. These cells are known to express a number of important suppressor molecules including IL-10, programmed cell death 1 (PD-1) and cytotoxic T lymphocyte antigen 4 (CTLA-4)<sup>[11]</sup>. Recently, fibrinogen-like protein 2 (FGL2) has been identified to be an important effector molecule of Treg<sup>[10,12]</sup>.

FGL2 is a member of the fibrinogen-like family of proteins, which was first isolated from a cytotoxic T cell library<sup>[13]</sup>. When expressed by macrophages and endothelial cells, FGL2 has prothrombinase activity, which contributes to the pathogenesis of experimental and human viral hepatitis<sup>[14-16]</sup>. When expressed by T cells, FGL2 has immunoregulatory activity<sup>[12,17]</sup>. The C-terminal of FGL2 contains a FRED domain, which accounts for the immunomodulatory activity and is important in regulating dendritic cell (DC) maturation, T cell proliferation and B cell apoptosis<sup>[12,17]</sup>. We and others have reported that Treg that express high levels of FGL2 lead to tolerance of fully mismatched heart allografts<sup>[18-20]</sup>. Studies showed that tolerant grafts contained large numbers of Treg that co-expressed Foxp3 and FGL2, whereas rejecting grafts contained Foxp3<sup>+</sup> Treg that were FGL2 negative. Depletion of Treg by antibody to CD25 or by a non-depleting antibody to FGL2 led to loss of tolerance and severe allograft rejection<sup>[18,19]</sup>.

We previously reported that mice lacking FGL2 (*fgl2<sup>-/-</sup>*) have a reduction in Treg immunosuppressive activity and develop autoimmune glomerulonephritis<sup>[12]</sup>. In those studies we showed that T cells from *fgl2<sup>-/-</sup>* mice are hyperproliferative and had a skewed Th1 profile, marked by increased IFN- $\gamma$  and reduced IL-4 expression. Both the number of DC and maturation of DC were increased in *fgl2<sup>-/-</sup>* mice. *Fgl2<sup>-/-</sup>* mice had a higher percentage of CD4<sup>+</sup>Foxp3<sup>+</sup> T cells in the thymus, spleen and lymph nodes compared with *fgl2<sup>+/+</sup>* mice; however, *fgl2<sup>-/-</sup>* Treg had decreased immune-suppressive activity compared with *fgl2<sup>+/+</sup>* Treg<sup>[12]</sup>.

To further determine the role of FGL2 in immune function, we generated ubiquitous FGL2 over-expressing mice (*fgl2<sup>Tg</sup>*)<sup>[20]</sup>. Here we used these mice to determine the importance of FGL2 to the pathogenesis of IBD. We examined both the ability of *fgl2<sup>Tg</sup>* T effector cells to induce colitis and the ability of *fgl2<sup>Tg</sup>* Treg to prevent colitis. We hypothesized that the over-expression of FGL2 in Treg would lead to protection against T cell-induced colitis.

## MATERIALS AND METHODS

### Animals

*fgl2*<sup>+/+</sup>, *fgl2*<sup>-/-</sup> and *fgl2*<sup>Tg</sup> mice were housed at the Ontario Cancer Institute Animal Resource Centre (Toronto, Canada). *Rag1*<sup>-/-</sup> and BALB/c mice were purchased from Jackson Laboratory (United States). Experiments were performed on mice 6-12 wk of age.

### Generation of FGL2 Transgenic Mice (*fgl2*<sup>Tg</sup>)

The generation of *fgl2*<sup>Tg</sup> mice has been previously reported<sup>[20]</sup>. Briefly, a prothrombinase inactive *fgl2* gene was inserted into the iZ/EG targeting vector, which was electroporated into R1 ES cells<sup>[21]</sup>. Chimeric mice were generated using the tetraploid embryo aggregation technique<sup>[21]</sup>. Following germline transmission, *fgl2*<sup>LoxP</sup> mice were crossed with *fgl2*<sup>-/-</sup> mice using the Jackson Laboratory speed congenic service followed by two crosses with EIIa-cre; *fgl2*<sup>-/-</sup> mice to generate *fgl2*<sup>Tg</sup> mice that co-overexpress FGL2 and EGFP ubiquitously. *fgl2*<sup>Tg</sup> mice used for these studies were further backcrossed to *fgl2*<sup>-/-</sup> mice on the C57BL/6 background to generate fully congenic mice (N10).

### Quantification of FGL2 expression

FGL2 concentrations in mouse plasma and culture supernatants were determined by a commercially available ELISA (BioLegend, United States).

### Flow cytometry

Cells were stained using a standard method described by the manufacturer (eBioscience, United States). In brief, a single cell suspension was incubated with Fc Block (eBioscience) on ice for 20 min. Cells were stained with CD4-PC7, CD4-PE-Cy7, Foxp3-PE, CD45RB-APC (eBioscience) and CD25-PE (Miltenyi Biotec, United States) in the dark for 30 min at 4 °C. Viability staining was performed using eFluor450 (eBioscience). For intracellular staining, cells previously stained for membrane proteins were fixed and permeabilized using a Fix/Perm kit (eBioscience). Cells were visualized using the BD LSRII analyzer (BD Biosciences, United States) and data were analyzed using FlowJo software, version 9.6 (Tree Star, United States).

### One way-mixed lymphocyte reaction

Single cell suspensions of BALB/c SMNC were generated using standard methods. BALB/c SMNC were irradiated with 2000cGy using a  $\gamma$ -irradiator. FACS sorted CD4<sup>+</sup>CD25<sup>-</sup> T cells were stained and labeled eFluor 670 dye as per manufacturer's instructions (eBioscience).  $4.0 \times 10^5$  BALB/c SMNC were incubated with  $2.0 \times 10^5$  *fgl2*<sup>+/+</sup> or *fgl2*<sup>Tg</sup> CD4<sup>+</sup> T cells in 96-well U-bottom plates at 37 °C for 3 d. Cells were then stained with anti-CD4-PE-Cy7 and eFluor 450 viability dye and analyzed using flow cytometry.

### Treg suppression assay


The Treg suppression assay was adapted from Shalev *et al.*<sup>[12]</sup>. *Fgl2*<sup>+/+</sup> or *fgl2*<sup>Tg</sup> lymphocytes were enriched for CD4<sup>+</sup> T cells using the Negative T cell Isolation kit (Miltenyi Biotec). The CD4<sup>-</sup> lymphocyte fraction was used as antigen presenting cells in the suppression assay. The CD4<sup>+</sup> enriched fractions were FACS sorted into CD4<sup>+</sup>CD25<sup>high</sup> Treg and CD4<sup>+</sup>CD25<sup>-</sup> T cells. All T cell populations were sorted to a purity > 98%. For the suppression assay,  $2 \times 10^5$  CD4<sup>-</sup> *fgl2*<sup>+/+</sup> antigen presenting cells were incubated with  $0.4 \times 10^5$  CD4<sup>+</sup>CD25<sup>-</sup> *fgl2*<sup>+/+</sup> T cells and serial dilutions of Treg (either *fgl2*<sup>+/+</sup> or *fgl2*<sup>Tg</sup>) starting with a 1:1 ratio of CD4<sup>+</sup>CD25<sup>-</sup> T cells to CD4<sup>+</sup>CD25<sup>+</sup> Treg. Cells were incubated in the presence of Concanavalin A at a final concentration of 1  $\mu$ g/mL for 3 d at 37 °C in RPMI-10. To measure proliferation, 1  $\mu$ Ci of <sup>3</sup>H-thymidine was added to culture supernatants and incubated for 18 h. Percent suppression was calculated as previously described<sup>[20]</sup>.

### T cell-induced model of colitis

The T cell-dependent model of colitis was adapted from Ostanin *et al.*<sup>[5]</sup>. Briefly, single cell suspensions of SMNC were enriched for CD4<sup>+</sup> T cells using the Negative T cell Isolation kit (Miltenyi Biotec). The CD4<sup>+</sup> enriched fraction was stained with CD4-PC7, CD45RB-APC (eBioscience) and CD25-PE (Miltenyi Biotec) and sorted on a BD FACS Aria II cell sorter (BD Biosciences, United States) into CD4<sup>+</sup>CD25<sup>+</sup>CD45RB<sup>low</sup> Treg and CD4<sup>+</sup>CD25<sup>-</sup>CD45RB<sup>high</sup> Teff. CD45RB<sup>low</sup> Treg and CD45RB<sup>high</sup> Teff were adjusted to a concentration of  $2 \times 10^6$  cells/mL and  $1 \times 10^7$  cells/mL respectively in Hank's balanced salt solution (HBSS). Sham treated mice were injected i.v. with 100  $\mu$ L of HBSS; the "no Treg" (Teff only) group was infused with  $0.5 \times 10^6$  CD45RB<sup>high</sup> *fgl2*<sup>+/+</sup> Teff cells; the *fgl2*<sup>+/+</sup> and *fgl2*<sup>Tg</sup> Treg-treated groups were infused with  $0.5 \times 10^6$  CD45RB<sup>high</sup> *fgl2*<sup>+/+</sup> Teff cells and  $0.1 \times 10^6$  CD45RB<sup>low</sup> Treg isolated from *fgl2*<sup>+/+</sup> or *fgl2*<sup>Tg</sup> mice. Mice were weighed weekly and were sacrificed at 14 wk post cell transfer or when they had lost 20% of body weight.

### Histology

Tissues were harvested and fixed in 10% buffered formalin solution. Following paraffin-embedding, tissues were sectioned at 4  $\mu$ m. The hematoxylin and eosin (H&E) stains were employed using standard methods. Staining for CD3<sup>+</sup> T cells and Foxp3<sup>+</sup> Treg was performed with anti-mouse CD3 (17A2; eBioscience) and anti-mouse Foxp3 (FJK-16S; eBioscience) antibodies. T cell proliferation was assessed by staining formalin fixed tissues with a rat anti-mouse Ki67 (TEC-3; DAKO, Denmark) followed by anti-rat Ig (Vector Laboratories, Canada). Pathological scoring was performed by a blinded pathologist using the scoring system adapted from Aranda *et al.*<sup>[3]</sup>. A maximum score



**Figure 1 Immunologic characterization of *fgl2<sup>Tg</sup>* mice.** A: Fibrinogen-like protein 2 (FGL2) plasma levels. Bar represents mean levels ( $n = 7-8$  mice/group); B: One-way MLR and FGL2 levels in MLR culture supernatants. FGL2 overexpression inhibits T cell proliferation in response to stimulation with BALB/c alloantigens. Proliferation was measured by flow cytometry. FGL2 levels in MLR culture supernatant were measured by an FGL2 ELISA. Data represent the mean  $\pm$  SD and are representative of three independent experiments; C: Foxp3<sup>+</sup> cell percentages in the thymus, spleen and lymph nodes. Foxp3<sup>+</sup> cells are represented as a percentage of total SMNC. Data are expressed as the mean  $\pm$  SD ( $n = 3$  mice/group); D: Treg suppression assay. The suppressive activity of Treg is expressed as a percent inhibition of T cell proliferation compared to responder T cells alone. Graphs show the mean  $\pm$  SD. Data are representative of 3 independent experiments. (<sup>a</sup> $P < 0.05$ , <sup>b</sup> $P < 0.01$ , <sup>e</sup> $P < 0.001$ ). MLR: Mixed lymphocyte reaction; SMNC: Splenic mononuclear cells; Treg: Regulatory T cell.

of 12 points was awarded based on the inflammatory infiltrate in the lamina propria (0-3), the degree of mucin depletion in the large intestine (0-3), the degree of intra-epithelial lymphocytes in the crypts (0-3) and the % of surface area affected (0-3).

**Morphometry**

CD3 and Foxp3 stained slides were scanned using the Aperio ScanScope Slide Scanner (Aperio Technologies, United States). Positively stained cells were counted with an algorithm developed with Spectrum software (Aperio Technologies).

**Animal Care and Use Statement**

All mice were housed in specific pathogen free conditions and fed a standard laboratory diet. Animals were treated in accordance with guidelines set by the Canadian Council for Animal Care and all appropriate measures were taken to minimize pain and discomfort. The animals were acclimatized to laboratory conditions (22 °C, 12 h/12 h light/dark, 50% humidity, *ad libitum* access for food and water) for two weeks prior to experimentation. All animals were euthanized by barbiturate overdose for tissue collection.

**Statistical analysis**


Statistical significance was determined using Students *t*-test or a one-way or two-way ANOVA as indicated using PRISM v5a (GraphPad Software, United States). *P*

values  $\leq 0.05$  were considered statistically significant.

**RESULTS**

**Alterations in T cell proliferation and Treg suppressive activity in *fgl2<sup>Tg</sup>* mice**

We previously reported on the generation of *fgl2<sup>Tg</sup>* mice that were backcrossed on a C57BL/6 background (N4)<sup>[20]</sup>. Here, we performed additional backcrosses to generate fully congenic *fgl2<sup>Tg</sup>* mice (N10). Congenic *fgl2<sup>Tg</sup>* mice maintained high expression of FGL2 with plasma levels of FGL2 that were approximately 9-fold higher than *fgl2<sup>+/+</sup>* mice ( $672.40 \pm 117.6$  ng/mL vs  $75.43 \pm 6.24$  ng/mL, respectively) (Figure 1A). To examine the effect of over-expression of FGL2 on T cell proliferation, CD4<sup>+</sup> T cells were isolated from *fgl2<sup>Tg</sup>* mice and stimulated with irradiated BALB/c splenic mononuclear cells (SMNC). Consistent with previous data showing that addition of recombinant FGL2 inhibited T cell proliferation *in-vitro*, *fgl2<sup>Tg</sup>* CD4<sup>+</sup> T cells were hypoproliferative compared with *fgl2<sup>+/+</sup>* CD4<sup>+</sup> T cells which is likely due to increased levels of FGL2 secreted by *fgl2<sup>Tg</sup>* CD4<sup>+</sup> T cells (Figure 1B)<sup>[17]</sup>. Previously, we showed that *fgl2<sup>-/-</sup>* Treg have decreased immunosuppressive activity and that Treg suppressive activity could be inhibited with anti-FGL2 antibody<sup>[12]</sup>. Additionally, we showed that *fgl2<sup>Tg</sup>* Treg expressed significantly higher levels of FGL2<sup>[20]</sup>. Here we found that there were no changes in the frequency of Foxp3<sup>+</sup>



**Figure 2** Isolation of CD4<sup>+</sup>CD25<sup>+</sup>CD45RB<sup>low</sup> Treg and CD4<sup>+</sup>CD25<sup>+</sup>CD45RB<sup>high</sup> Teff. A: Representative flow plots of CD4 vs CD25 populations. SMNC were isolated and enriched for CD4<sup>+</sup> T cells by negative T cell selection using magnetic cell sorting. CD4<sup>+</sup> T cells fractions were stained with CD4<sup>+</sup>-PE-Cy7, CD25<sup>+</sup>-PE and CD45RB-APC and sorted into CD4<sup>+</sup>CD25<sup>+</sup>CD45RB<sup>low</sup> and CD4<sup>+</sup>CD25<sup>+</sup>CD45RB<sup>high</sup> T cell fractions. Cells were gated on live cells, singlets and CD4<sup>+</sup> populations. Plots show initial SMNC population and the CD4<sup>+</sup>CD25<sup>+</sup> and CD4<sup>+</sup>CD25<sup>-</sup> T cell populations following FACS sorting; B: Histogram of CD45RB cell distribution; C: Flow plots of CD25 vs CD45RB populations. Final populations of CD4<sup>+</sup>CD25<sup>+</sup>CD45RB<sup>low</sup> and CD4<sup>+</sup>CD25<sup>+</sup>CD45RB<sup>high</sup> T cell fractions were > 98% pure. SMNC: Splenic mononuclear cells; Teff: Effector T cell; Treg: Regulatory T cell.


cells in *fgl2*<sup>Tg</sup> mice compared with *fgl2*<sup>+/+</sup> mice (Figure 1C), but *fgl2*<sup>Tg</sup> Treg had increased immunosuppressive activity compared with *fgl2*<sup>+/+</sup> Treg (Figure 1D).

### *Fgl2*<sup>Tg</sup> Treg have enhanced activity to prevent T cell induced colitis

We next studied the effect of *fgl2*<sup>Tg</sup> Treg on the development of colitis<sup>[2-4]</sup>. For these studies, we isolated CD4<sup>+</sup>CD25<sup>+</sup>CD45RB<sup>low</sup> Treg and CD4<sup>+</sup>CD25<sup>+</sup>CD45RB<sup>high</sup> Teff with a purity of > 98% using FACS (Figure 2). *Rag1*<sup>-/-</sup> mice received by tail vein injection 0.5 × 10<sup>6</sup> CD4<sup>+</sup>CD25<sup>+</sup>CD45RB<sup>high</sup> T cells isolated from *fgl2*<sup>+/+</sup> mice and were sacrificed 14 wk post-injection. Mice were monitored for signs of disease including, lethargy, piloerection, hunching, dehydration and weight loss. *Rag1*<sup>-/-</sup> mice that received CD4<sup>+</sup>CD25<sup>+</sup>CD45RB<sup>high</sup> T cells developed clinical signs of disease, including decreased activity and piloerection. In contrast to sham mice, these mice did not gain weight post-transfer of Teff cells (Figure 3A). Mice that received *fgl2*<sup>-/-</sup> or *fgl2*<sup>+/+</sup> Treg showed improved clinical activity within the first

4-6 wk, but these mice still demonstrated clinical signs of colitis including lethargy, piloerection and slight hunching. In contrast, all mice that received *fgl2*<sup>Tg</sup> Treg appeared clinically normal and had weight gain similar to sham control mice (Figure 3A).

Tissues were harvested and examined histologically from the ileum, the proximal, medial and distal colon at 14 wk post cell transfer. In all groups of mice, the ileum was near normal similar to what has been reported previously by other investigators<sup>[5]</sup>. As expected, the sham group showed normal colonic architecture with large numbers of goblet cells and normal crypt architecture (Figure 3B). In contrast, colons from mice that received Teff but no Treg cells showed large, diffuse areas of parenchymal disease characterized by villous flattening, large cellular infiltrates, destruction of crypts, severe mucin depletion and loss of goblet cells (Figure 3B). Colons from mice that received *fgl2*<sup>-/-</sup> or *fgl2*<sup>+/+</sup> Treg had improved histology but still had patchy areas of colitis marked by T cell infiltrates, destruction of epithelial



**Figure 3** *fgl2*<sup>Tg</sup> Treg protect against colitis. A: Effect of Treg on clinical course of disease as determined by weight. Mice were weighed weekly and were sacrificed at 14 wk post cell transfer. Mice that received *fgl2*<sup>Tg</sup> Treg gained weight similar to the sham group of mice, whereas all other groups had reduced weight gain ( $n \geq 5$  mice/group); B: Histology of colons. Sham colons had normal villous architecture with abundant goblet cells. Colons from the no Treg group showed prominent features of severe colitis with dense cellular infiltration, edema, and abscess formation as well as loss of goblet cells. Infusion of *fgl2*<sup>-/-</sup> or *fgl2*<sup>+/+</sup> Treg led to overall improved histology; however, numerous areas of patchy colonic disease were still seen. In contrast, colons from mice that received *fgl2*<sup>Tg</sup> Treg were near normal. H&E; Original magnification 100  $\times$ ; C: Pathologic scoring of colon sections. Scoring was performed on H&E stained sections as described in the methods section. Data represent mean  $\pm$  SEM. Pathology scores were obtained from 2 independent experiments with  $n \geq 5$  mice per group; D: Transfer of *fgl2*<sup>Tg</sup> Treg does not alter FGL2 plasma levels during colitis. Blood from *fgl2*<sup>+/+</sup>, *Rag1*<sup>-/-</sup> and *fgl2*<sup>Tg</sup> mice was collected prior to the induction of colitis (plasma levels in naïve mice). At sacrifice, blood was collected from each animal. *Rag1*<sup>-/-</sup> mice received CD4<sup>+</sup>CD25<sup>+</sup>CD45RB<sup>hi</sup> T cells and Treg isolated from *fgl2*<sup>+/+</sup> or *fgl2*<sup>Tg</sup> mice (Treg adoptively transferred into *Rag1*<sup>-/-</sup> mice). Plasma levels of FGL2 were measured using an FGL2 ELISA. Statistical analysis was performed using a one-way ANOVA and Tukey's multiple comparison post-hoc test (<sup>a</sup> $P < 0.05$ , <sup>e</sup> $P < 0.001$ ). Treg: Regulatory T cells.

crypts, mucin depletion and reduced numbers of goblet cells. Histologically, the colons from *fgl2<sup>Tg</sup>* Treg treated group were near normal with preserved goblet cells and few if any mononuclear cell infiltrates. *Fgl2<sup>-/-</sup>* mice had more severe disease compared to mice that received *fgl2<sup>+/+</sup>* Treg, but by morphometry the difference in severity of colonic disease did not reach statistical significance (Figure 3B).

Changes in histology were quantified using a modified pathology index established by Aranda *et al.*<sup>[3]</sup> with a maximum pathology score of 12. Mice in the no Treg group had the highest score indicative of a pan diffuse colitis with disease across the proximal, mid and distal colon associated with diffuse parenchymal destruction, crypt loss, mucin depletion and dense lymphocyte infiltrates (Figure 3C). Mice that received *fgl2<sup>-/-</sup>* or *fgl2<sup>+/+</sup>* Treg had similar overall pathology scores, which were significantly better than mice in the no Treg group. Colons from mice that received *fgl2<sup>Tg</sup>* Treg were near normal with normal numbers of crypt goblet cells; however, there were occasional patchy foci of inflammation and small numbers of crypt abscesses seen especially in the mid colon. These mice had a pathology score that was significantly better than mice that received either *fgl2<sup>-/-</sup>* or *fgl2<sup>+/+</sup>* Treg (Figure 3C).

To determine if adoptive transfer of *fgl2<sup>Tg</sup>* Treg could alter systemic levels of FGL2 we measured plasma levels of FGL2 in the *Rag1<sup>-/-</sup>* mice. Interestingly, we found that there was no change in plasma levels of FGL2 following transfer of *fgl2<sup>Tg</sup>* Treg (Figure 3D). These data suggest that the adoptively transferred *fgl2<sup>Tg</sup>* Treg are working locally as opposed to systemically to limit colonic inflammation.

### ***Fgl2<sup>Tg</sup>* Treg prevent infiltration of Teff into the colon of *Rag1<sup>-/-</sup>* mice**

The colon and mesenteric lymph nodes (MLN) from all groups of mice were stained for the presence of CD3<sup>+</sup> T cells and Foxp3<sup>+</sup> Treg cells. As expected, colons from the sham group of mice had no CD3<sup>+</sup> T cells (Figure 4A). Mice that received only Teff contained large numbers of CD3<sup>+</sup> T cell infiltrates in association with areas of colitis (Figure 4A). Mice that received both Teff cells and *fgl2<sup>+/+</sup>* Treg had reduced numbers of CD3<sup>+</sup> T cells compared to mice that were treated with Teff cells only, but CD3<sup>+</sup> T cells were still present in the lamina propria in proximity to areas of colitis. In contrast, mice that received Teff cells and *fgl2<sup>Tg</sup>* Treg had very few CD3<sup>+</sup> T cells within the colon (Figure 4A). Colon sections were also stained for Foxp3 (Figure 4A). As expected, Foxp3<sup>+</sup> Treg were not found in sham control mice or mice that only received Teff. In the *fgl2<sup>+/+</sup>* and *fgl2<sup>Tg</sup>* Treg treated groups Foxp3<sup>+</sup> cells were found throughout the colon (Figure 4A). These findings were confirmed by morphometry (Figure 4C-E). The ratio of Foxp3<sup>+</sup> to CD3<sup>+</sup> cells was highest in mice that received *fgl2<sup>Tg</sup>* Treg ( $P < 0.001$ ) (Figure 4E).

Mesenteric lymph nodes (MLN) from sham mice

had very few CD3<sup>+</sup> but did not stain for Foxp3. Large numbers of CD3<sup>+</sup> T cells were seen in the MLN of all the groups of mice that were infused with Teff cells consistent with reconstitution of the immune system. Very few Foxp3<sup>+</sup> T cells were seen in mice that received Teff alone or Teff and *fgl2<sup>+/+</sup>* Treg. In contrast, large numbers of Foxp3<sup>+</sup> cells were seen in the MLN of mice that received *fgl2<sup>Tg</sup>* Treg, leading to a high Foxp3<sup>+</sup> to CD3<sup>+</sup> cell ratio (Figure 4B-E).

### **Effect of Treg on T Cell Proliferation assessed by Ki67 staining**


To examine the influence of Treg on Teff cell proliferation, Ki67 staining was performed as described in the methods and by others<sup>[22]</sup>. In sham mice, Ki67<sup>+</sup> cells were seen primarily in the cortex of the MLN, and in mice that received Teff alone, there were increased clusters of Ki67<sup>+</sup> cells, primarily localized to the cortex of the MLN. MLN from mice that received *fgl2<sup>+/+</sup>* Treg also contained significant numbers of Ki67<sup>+</sup> cells, although they were more diffusely spread within the MLN. In contrast, mice that received *fgl2<sup>Tg</sup>* Treg had only small numbers of Ki67<sup>+</sup> cells similar to sham mice. As opposed to sham mice, mice that were reconstituted with Teff alone had large numbers of Ki67<sup>+</sup> cells both within the lamina propria and epithelium, coincident with areas of histologic colitis. Mice that received *fgl2<sup>+/+</sup>* Treg also had foci of Ki67<sup>+</sup> cells in the lamina propria and epithelium. In contrast, no Ki67<sup>+</sup> staining was seen in these areas in mice that received *fgl2<sup>Tg</sup>* Treg. Ki67<sup>+</sup> staining was seen in the colonic crypts of all groups of mice as expected (Figure 5).

### ***Fgl2<sup>Tg</sup>* Teff do not induce colitis in *Rag1<sup>-/-</sup>* mice**

To examine the effect of FGL2 over expression of Teff function, Teff cells were isolated from *fgl2<sup>Tg</sup>* or *fgl2<sup>+/+</sup>* mice and infused into *Rag1<sup>-/-</sup>* recipients. As discussed above, all mice that received *fgl2<sup>+/+</sup>* Teff, developed severe colitis, whereas none of the mice that received *fgl2<sup>Tg</sup>* Teff developed clinical or histologic signs of colitis (Figure 6A and B). MLN from mice receiving either *fgl2<sup>Tg</sup>* or *fgl2<sup>+/+</sup>* Teff were repopulated with CD3 cells; however, CD3<sup>+</sup> cell infiltrates were only seen in the colons of mice that received *fgl2<sup>+/+</sup>* Teff in association with areas of severe colitis (Figure 6C).

## **DISCUSSION**

IBD consists of a group of chronic relapsing inflammatory diseases of the gastrointestinal tract that include CD and ulcerative colitis<sup>[1]</sup>. The onset of colitis has been shown to be dependent on dysregulated innate and adaptive immune responses to bacterial flora<sup>[1-5]</sup>. Here we investigated the effect of overexpression of the Treg immunosuppressive effector molecule FGL2 in the T cell-induced mouse model of colitis. For these studies, we isolated Treg and Teff cells from transgenic mice that ubiquitously




**Figure 4** Foxp3<sup>+</sup> Treg are increased and CD3<sup>+</sup> T cells are decreased in mice that received *fgl2*<sup>Tg</sup> Treg. A: Representative photomicrographs of CD3 and Foxp3 staining of colonic sections. Sham colons were negative for both CD3 and Foxp3. Mice that received Teff and no Treg or *fgl2*<sup>+/+</sup> Treg had large numbers of CD3<sup>+</sup> T cells in the lamina propria and epithelium, whereas colons from mice that received *fgl2*<sup>Tg</sup> Treg had only patchy CD3<sup>+</sup> T cell infiltrates. Original magnification × 100; B: Representative photomicrographs of CD3 and Foxp3 staining of MLN sections. MLN from sham mice had very few CD3<sup>+</sup> cells. In contrast, large numbers of CD3<sup>+</sup> T cells were seen in the MLN of the other groups of mice. Treg staining was absent in the MLN of sham mice and very few Foxp3<sup>+</sup> cells were seen in mice that only received Teff or mice that received *fgl2*<sup>+/+</sup> Treg, whereas large numbers of Foxp3<sup>+</sup> cells were seen in mice that received *fgl2*<sup>Tg</sup> Treg. Original magnification × 100; C: Absolute numbers of CD3<sup>+</sup> cells by morphometry (cells/mm<sup>2</sup>); D: Absolute numbers of Foxp3<sup>+</sup> T cells by morphometry (cells/mm<sup>2</sup>); E: Ratio of Foxp3<sup>+</sup> to CD3<sup>+</sup> T cells in each tissue section. Data represent the mean ± SD. Quantification is based on two independent experiments with *n* ≥ 5 mice per group (<sup>a</sup>*P* < 0.05, <sup>b</sup>*P* < 0.01, <sup>e</sup>*P* < 0.001). MLN: Mesenteric lymph nodes; Teff: Effector T cells; Treg: Regulatory T cells.

overexpress FGL2, which were recently generated in our laboratory<sup>[20]</sup>. *In vitro*, *fgl2*<sup>Tg</sup> Treg had enhanced suppressive activity compared with *fgl2*<sup>+/+</sup> Treg, and *fgl2*<sup>Tg</sup> CD4<sup>+</sup> T cells had reduced proliferative potential compared with *fgl2*<sup>+/+</sup> CD4<sup>+</sup> T cells. *In vivo*, *fgl2*<sup>Tg</sup> Treg were superior to *fgl2*<sup>+/+</sup> Treg in preventing colitis. This was accompanied by increased ratios of Foxp3<sup>+</sup> Treg to CD3<sup>+</sup> T cells in the colon and MLN. In mice treated

with *fgl2*<sup>Tg</sup> Treg, there was also reduced proliferation of Teff cells as assessed by Ki67 staining. Furthermore, *fgl2*<sup>Tg</sup> Teff cells failed to induce colitis.

Treg are known to regulate the differentiation and proliferation of Teff by several mechanisms, including bystander suppression and/or by altering the cytokine milieu<sup>[11]</sup>. IL-10 has been shown to be important in the prevention of experimental IBD through binding with



**Figure 5** *Fgl2*<sup>Tg</sup> Treg prevent proliferation of infiltrating T cells in the colon. CD3<sup>+</sup> T cell proliferation in the MLN and colon were examined by Ki67 staining at week 14. Ki67<sup>+</sup> cells were seen primarily in the cortex of the MLN of sham mice. Mice that received Teff had increased clusters of Ki67<sup>+</sup> cells, primarily within the cortex. Mice that received *fgl2*<sup>+/+</sup> Treg also had significant numbers of Ki67<sup>+</sup> cells, whereas mice that received *fgl2*<sup>Tg</sup> Treg had similar numbers of Ki67<sup>+</sup> cells as sham mice. Ki67<sup>+</sup> cells were only seen in the colonic crypts of sham mice. Mice that were reconstituted with Teff alone had large numbers of Ki67<sup>+</sup> cells both within the lamina propria and epithelium, coincident with areas of colonic inflammation. Mice that received *fgl2*<sup>+/+</sup> Treg had small foci of Ki67<sup>+</sup> cells in the lamina propria and epithelium whereas no Ki67<sup>+</sup> staining was seen in these areas in mice that received *fgl2*<sup>Tg</sup> Treg. In all groups of mice colonic crypt cells stained positively for Ki67 as expected. Original magnification × 100. MLN: Mesenteric lymph nodes; Teff: Effector T cells; Treg: Regulatory T cells.


its receptor leading to expansion of Treg. Interestingly, Treg from IL-10 knock mice (*IL-10*<sup>-/-</sup>) are as effective as Treg from normal mice in protecting against IBD suggesting that although IL-10 is important in protection against colitis, the source of IL-10 need not be from Treg<sup>[23]</sup>. FGL2 has previously been described as an important Treg immunosuppressive effector molecule<sup>[12]</sup>. Recently, FGL2 was shown to be critical for the immune suppressive activity of a major subset of Treg that express T cell immunoglobulin and ITIM domain (TIGIT)<sup>[10]</sup>. In those studies, TIGIT<sup>+</sup> Treg were shown to highly suppress TH1 and TH17 cell responses while preserving TH2 responses, which was dependent on FGL2 expression<sup>[10]</sup>. Both TIGIT<sup>-/-</sup> Treg and TIGIT<sup>+</sup> Treg inhibited T cell-induced colitis, but the role of FGL2 in colitis was not examined in their report<sup>[10]</sup>.

Others have reported that Treg can ameliorate Teff induced colitis in the *Rag1*<sup>-/-</sup> mouse model<sup>[2]</sup>. Although mice infused with Treg had markedly reduced colitis, Treg treated mice still had evidence of disease as

reflected by histology and pathologic scoring<sup>[2]</sup>. The results presented here demonstrate that *fgl2*<sup>Tg</sup> Treg are superior to *fgl2*<sup>+/+</sup> Treg both in suppressive activity *in vitro* and in prevention of colitis *in vivo*. Interestingly, adoptive transfer of *fgl2*<sup>Tg</sup> Treg compared with *fgl2*<sup>+/+</sup> Treg led to greater number of Treg in the MLN and less Teff proliferation in the MLN. These data are supportive of the hypothesis that *fgl2*<sup>Tg</sup> Treg in comparison to *fgl2*<sup>+/+</sup> Treg prevent colitis by preventing activation of Teff in the MLN, which then inhibits homing of Teff to the colon<sup>[10]</sup>. The increased numbers of *fgl2*<sup>Tg</sup> Treg compared with *fgl2*<sup>+/+</sup> Treg in the MLN may be the result of either enhanced homing of *fgl2*<sup>Tg</sup> Treg cells to the MLN, changes in *fgl2*<sup>Tg</sup> Treg survival/proliferation or the induction of Treg from naïve T cells. Recently, we reported that Treg from *fgl2*<sup>Tg</sup> mice promote tolerance in a fully MHC mismatched mouse model of heart transplantation<sup>[20]</sup>. We also reported that tolerant heart allografts contain increased numbers of FGL2<sup>+</sup> Treg whereas they were near absent in rejecting allografts<sup>[18]</sup>. Taken together, these data suggest Treg secreting high levels of FGL2 are critical to the establishment and maintenance of tolerance in both allo-transplantation and autoimmune disease. Clinical trials are currently underway to test the safety and efficacy of Treg populations in the treatment of IBD<sup>[24,25]</sup>. We propose that expansion of FGL2<sup>high</sup> Treg may be a highly effective approach to treating patients with autoimmune disease, including IBD.

Through the generation of *fgl2*<sup>Tg</sup> mice, we have confirmed that FGL2 is an important immune modulator that regulates Teff cell function and proliferation. We demonstrate here that *fgl2*<sup>Tg</sup> Teff in contrast to *fgl2*<sup>+/+</sup> Teff are not capable of inducing colitis in *Rag1*<sup>-/-</sup> mice. Previously, we demonstrated that the inhibitory Fcγ receptor (FcγRIIB), which is expressed on antigen presenting cells (APC) such as DC and B cells, is the receptor for FGL2<sup>[26,27]</sup>. We also showed that recombinant FGL2 inhibits the maturation of bone marrow-derived DC and promotes B cell apoptosis<sup>[26]</sup>. It is unlikely that FGL2 acts directly on Teff as T cells express little if any FcγRIIB<sup>[27]</sup>. Consistent with this, we have observed that recombinant FGL2 did not inhibit T cell proliferation when purified T cells were stimulated with anti-CD3 and anti-CD28 (data not shown). However, recombinant FGL2 inhibits T cell proliferation in mixed lymphocyte reactions when APC are present<sup>[28]</sup>. The inhibition on DC maturation by FGL2 may explain why mice infused with *fgl2*<sup>Tg</sup> Teff had reduced numbers in the colon. We hypothesize that the increased expression of FGL2 by *fgl2*<sup>Tg</sup> Teff inhibits the maturation of DCs encountered in the inflamed tissue which, in turn, inhibits the activation and expansion of the same Teff in a negative feedback loop. We cannot rule out at this time, however, that there is an intrinsic defect in *fgl2*<sup>Tg</sup> CD4<sup>+</sup> T cells due to overexpression of FGL2.

A recent paper has demonstrated increased mucosal biopsy staining for FGL2 and increased plasma



**Figure 6** *fgl2*<sup>Tg</sup> Teff do not induce colitis. A: Histopathology. *Rag1*<sup>-/-</sup> mice that received *fgl2*<sup>+/+</sup> Teff had histologic evidence of severe colitis with dense CD3<sup>+</sup> T cell infiltrates, edema, crypt and goblet cell loss and abscess formation. Colons from mice that received *fgl2*<sup>Tg</sup> Teff were near normal. H&E; Original magnification × 100; B: Extent of disease in the colon was confirmed by pathologic scoring. Three sections of the colon were scored as described in the methods. Data are the mean ± SD; C: Immunohistochemistry of CD3<sup>+</sup> staining in the colon (left column) or MLN (right column) showing repopulation of MLN in mice that received either *fgl2*<sup>Tg</sup> or *fgl2*<sup>+/+</sup> Teff. Dense infiltrates of CD3<sup>+</sup> cells were only seen in the colons of mice that received *fgl2*<sup>+/+</sup> Teff and not *fgl2*<sup>Tg</sup> Teff. Original magnification × 100. Data represent *n* = 3 mice per group (<sup>b</sup>*P* < 0.01, <sup>e</sup>*P* < 0.001). MLN: Mesenteric lymph nodes; Teff: Effector T cells.

levels of FGL2 in patients with active IBD (CD and ulcerative colitis)<sup>[29]</sup>. In these patients, endothelial cells and infiltrating inflammatory cells in mucosal biopsy specimens stained strongly for FGL2. Together with our studies showing the immunosuppressive effects of FGL2, these data suggest that expression of FGL2 is an important regulator of mucosal immunity and may represent a feedback mechanism to limit inflammation in patients with active IBD<sup>[29]</sup>.

Collectively, the studies presented here confirm that FGL2 is an important immunosuppressive effector. Teff from *fgl2*<sup>Tg</sup> mice are hypoproliferative and fail to induce colitis when injected into *Rag1*<sup>-/-</sup> mice. Treg from *fgl2*<sup>Tg</sup> have increased immunosuppressive activity *in vitro* and protect mice from T cell-mediated colitis. These studies support the concept that FGL2 expressing Treg are critical for the maintenance of tolerance and provide a rationale for exploring the use of recombinant FGL2 or Treg expressing high levels of FGL2 in the treatment of autoimmune disease.

## COMMENTS

### Background

Inflammatory bowel disease (IBD) consists of a group of chronic relapsing inflammatory diseases of the gastrointestinal tract that include Crohn's disease and ulcerative colitis. Regulatory T cells (Treg) have been shown to be important regulators of disease activity in IBD and can ameliorate disease in the T cell-induced model of colitis in immunodeficient *Rag1*<sup>-/-</sup> mice.

### Research frontiers

Fibrinogen-like protein 2 (FGL2) is a newly described immunoregulatory molecule that is an effector molecule of Treg. The effect of overexpression of FGL2 in the T cell-induced model of colitis has not been studied previously. We recently generated a transgenic line of mice that ubiquitously overexpress FGL2 (*fgl2*<sup>Tg</sup>). Here we isolated Treg and effector T cells (Teff) from *fgl2*<sup>Tg</sup> mice and compared these cells to wildtype (*fgl2*<sup>+/+</sup>) cells in the T cell-induced colitis model.

### Innovations and breakthroughs

The authors found that *fgl2*<sup>Tg</sup> Treg have enhanced immune suppressive activity compared with *fgl2*<sup>+/+</sup> Treg *in vitro*. Following injection in *Rag1*<sup>-/-</sup> mice, *fgl2*<sup>Tg</sup> Treg were present in high numbers in mesenteric lymph nodes and were superior to

*fgl2<sup>hi</sup>* Treg in preventing T cell-induced colitis. *Fgl2<sup>hi</sup>* Teff were hypoproliferative *in vitro* and were not capable of inducing colitis.

### Applications

Overexpression of FGL2 by either Treg or Teff prevents T cell-mediated colitis. These studies collectively provide a rationale for exploring the use of either recombinant FGL2 or Treg expressing high levels of FGL2 in the treatment of inflammatory bowel disease.

### Terminology

FGL2 is an immunoregulatory molecule that has been shown to be an effector molecule of Treg.

### Peer-review

This is an excellent, but descriptive, paper. The experiment proposed in the comments to authors may provide a link between the two disparate observations described.

## REFERENCES

- Sartor RB.** Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. *Nat Clin Pract Gastroenterol Hepatol* 2006; **3**: 390-407 [PMID: 16819502 DOI: 10.1038/ncpgasthep0528]
- Powrie F, Leach MW, Mauze S, Caddle LB, Coffman RL.** Phenotypically distinct subsets of CD4+ T cells induce or protect from chronic intestinal inflammation in C. B-17 scid mice. *Int Immunol* 1993; **5**: 1461-1471 [PMID: 7903159]
- Aranda R, Sydora BC, McAllister PL, Binder SW, Yang HY, Targan SR, Kronenberg M.** Analysis of intestinal lymphocytes in mouse colitis mediated by transfer of CD4+, CD45RBhigh T cells to SCID recipients. *J Immunol* 1997; **158**: 3464-3473 [PMID: 9120308]
- Morrissey PJ, Charrier K, Braddy S, Liggitt D, Watson JD.** CD4+ T cells that express high levels of CD45RB induce wasting disease when transferred into congenic severe combined immunodeficient mice. Disease development is prevented by cotransfer of purified CD4+ T cells. *J Exp Med* 1993; **178**: 237-244 [PMID: 8100269]
- Ostanin DV, Bao J, Koboziev I, Gray L, Robinson-Jackson SA, Kosloski-Davidson M, Price VH, Grisham MB.** T cell transfer model of chronic colitis: concepts, considerations, and tricks of the trade. *Am J Physiol Gastrointest Liver Physiol* 2009; **296**: G135-G146 [PMID: 19033538 DOI: 10.1152/ajpgi.90462.2008]
- Singh B, Read S, Asseman C, Malmström V, Mottet C, Stephens LA, Stepankova R, Tlaskalova H, Powrie F.** Control of intestinal inflammation by regulatory T cells. *Immunol Rev* 2001; **182**: 190-200 [PMID: 11722634]
- Zhang N, Schröppel B, Lal G, Jakubzick C, Mao X, Chen D, Yin N, Jessberger R, Ochando JC, Ding Y, Bromberg JS.** Regulatory T cells sequentially migrate from inflamed tissues to draining lymph nodes to suppress the alloimmune response. *Immunity* 2009; **30**: 458-469 [PMID: 19303390 DOI: 10.1016/j.immuni.2008.12.022]
- Williams LM, Rudensky AY.** Maintenance of the Foxp3-dependent developmental program in mature regulatory T cells requires continued expression of Foxp3. *Nat Immunol* 2007; **8**: 277-284 [PMID: 17220892 DOI: 10.1038/ni1437]
- Hori S, Nomura T, Sakaguchi S.** Control of regulatory T cell development by the transcription factor Foxp3. *Science* 2003; **299**: 1057-1061 [PMID: 12522256 DOI: 10.1126/science.1079490]
- Joller N, Lozano E, Burkett PR, Patel B, Xiao S, Zhu C, Xia J, Tan TG, Sefik E, Yajnik V, Sharpe AH, Quintana FJ, Mathis D, Benoist C, Hafler DA, Kuchroo VK.** Treg cells expressing the coinhibitory molecule TIGIT selectively inhibit proinflammatory Th1 and Th17 cell responses. *Immunity* 2014; **40**: 569-581 [PMID: 24745333 DOI: 10.1016/j.immuni.2014.02.012]
- Shevach EM.** Mechanisms of foxp3+ T regulatory cell-mediated suppression. *Immunity* 2009; **30**: 636-645 [PMID: 19464986 DOI: 10.1016/j.immuni.2009.04.010]
- Shalev I, Liu H, Kosciak C, Bartczak A, Javadi M, Wong KM, Maknojia A, He W, Liu MF, Diao J, Winter E, Manuel J, McCarthy D, Cattral M, Gomerman J, Clark DA, Phillips MJ, Gorchynski RR, Zhang L, Downey G, Grant D, Cybulsky MI, Levy G.** Targeted deletion of *fgl2* leads to impaired regulatory T cell activity and development of autoimmune glomerulonephritis. *J Immunol* 2008; **180**: 249-260 [PMID: 18097026]
- Koyama T, Hall LR, Haser WG, Tonegawa S, Saito H.** Structure of a cytotoxic T-lymphocyte-specific gene shows a strong homology to fibrinogen beta and gamma chains. *Proc Natl Acad Sci USA* 1987; **84**: 1609-1613 [PMID: 3550794]
- Ding JW, Ning Q, Liu MF, Lai A, Leibowitz J, Peltekian KM, Cole EH, Fung LS, Holloway C, Marsden PA, Yeager H, Phillips MJ, Levy GA.** Fulminant hepatic failure in murine hepatitis virus strain 3 infection: tissue-specific expression of a novel *fgl2* prothrombinase. *J Virol* 1997; **71**: 9223-9230 [PMID: 9371581]
- Parr RL, Fung L, Reneker J, Myers-Mason N, Leibowitz JL, Levy G.** Association of mouse fibrinogen-like protein with murine hepatitis virus-induced prothrombinase activity. *J Virol* 1995; **69**: 5033-5038 [PMID: 7609073]
- Chan CW, Chan MW, Liu M, Fung L, Cole EH, Leibowitz JL, Marsden PA, Clark DA, Levy GA.** Kinetic analysis of a unique direct prothrombinase, *fgl2*, and identification of a serine residue critical for the prothrombinase activity. *J Immunol* 2002; **168**: 5170-5177 [PMID: 11994472]
- Chan CW, Kay LS, Khadaroo RG, Chan MW, Lakatoo S, Young KJ, Zhang L, Gorchynski RM, Cattral M, Rotstein O, Levy GA.** Soluble fibrinogen-like protein 2/fibroleukin exhibits immunosuppressive properties: suppressing T cell proliferation and inhibiting maturation of bone marrow-derived dendritic cells. *J Immunol* 2003; **170**: 4036-4044 [PMID: 12682232]
- Urbanellis P, Shyu W, Khattar R, Wang J, Zakharova A, He W, Sadozai H, Amir AZ, Shalev I, Phillips MJ, Adeyi O, Ross H, Grant D, Levy GA, Chruscinski A.** The regulatory T cell effector molecule fibrinogen-like protein 2 is necessary for the development of rapamycin-induced tolerance to fully MHC-mismatched murine cardiac allografts. *Immunology* 2015; **144**: 91-106 [PMID: 24990517 DOI: 10.1111/imm.12354]
- Li XL, Ménoret S, Bezie S, Caron L, Chabannes D, Hill M, Halary F, Angin M, Heslan M, Usal C, Liang L, Guillonnet C, Le Mauff B, Cuturi MC, Josien R, Anegón I.** Mechanism and localization of CD8 regulatory T cells in a heart transplant model of tolerance. *J Immunol* 2010; **185**: 823-833 [PMID: 20543104 DOI: 10.4049/jimmunol.1000120]
- Bartczak A, Chruscinski A, Mendicino M, Liu H, Zhang J, He W, Amir AZ, Nguyen A, Khattar R, Sadozai H, Lobe CG, Adeyi O, Phillips MJ, Zhang L, Gorchynski RM, Grant D, Levy GA.** Overexpression of Fibrinogen-Like Protein 2 Promotes Tolerance in a Fully Mismatched Murine Model of Heart Transplantation. *Am J Transplant* 2016; **16**: 1739-1750 [PMID: 26718313 DOI: 10.1111/ajt.13696]
- Lobe CG, Koop KE, Kreppner W, Lomeli H, Gertsenstein M, Nagy A.** Z/AP, a double reporter for cre-mediated recombination. *Dev Biol* 1999; **208**: 281-292 [PMID: 10191045 DOI: 10.1006/dbio.1999.9209]
- Scholzen T, Gerdes J.** The Ki-67 protein: from the known and the unknown. *J Cell Physiol* 2000; **182**: 311-322 [PMID: 10653597 DOI: 10.1002/(SICI)1097-4652(200003)182]
- Murai M, Turovskaya O, Kim G, Madan R, Karp CL, Cheroutre H, Kronenberg M.** Interleukin 10 acts on regulatory T cells to maintain expression of the transcription factor Foxp3 and suppressive function in mice with colitis. *Nat Immunol* 2009; **10**: 1178-1184 [PMID: 19783988 DOI: 10.1038/ni.1791]
- Desreumaux P, Foussat A, Allez M, Beaugerie L, Hébuterne X, Bouhnik Y, Nachury M, Brun V, Bastian H, Belmonte N, Ticchioni M, Duchange A, Morel-Mandrino P, Neveu V, Clerget-Chossat N, Forte M, Colombel JF.** Safety and efficacy of antigen-specific regulatory T-cell therapy for patients with refractory Crohn's disease. *Gastroenterology* 2012; **143**: 1207-1217.e1-2 [PMID: 22853333 DOI: 10.1053/j.gastro.2012.07.116]

- 25 **Lord JD.** Promises and paradoxes of regulatory T cells in inflammatory bowel disease. *World J Gastroenterol* 2015; **21**: 11236-11245 [PMID: 26523099 DOI: 10.3748/wjg.v21.i40.11236]
- 26 **Liu H,** Shalev I, Manuel J, He W, Leung E, Crookshank J, Liu MF, Diao J, Cattral M, Clark DA, Isenman DE, Gorczynski RM, Grant DR, Zhang L, Phillips MJ, Cybulsky MI, Levy GA. The FGL2-FcγRIIB pathway: a novel mechanism leading to immunosuppression. *Eur J Immunol* 2008; **38**: 3114-3126 [PMID: 18991288 DOI: 10.1002/eji.200838338]
- 27 **Nimmerjahn F,** Ravetch JV. Fcγ receptors: old friends and new family members. *Immunity* 2006; **24**: 19-28 [PMID: 16413920 DOI: 10.1016/j.immuni.2005.11.010]
- 28 **Liu H,** Yang PS, Zhu T, Manuel J, Zhang J, He W, Shalev I, Zhang L, Cybulsky MI, Grant DR, Phillips MJ, Levy GA. Characterization of fibrinogen-like protein 2 (FGL2): monomeric FGL2 has enhanced immunosuppressive activity in comparison to oligomeric FGL2. *Int J Biochem Cell Biol* 2013; **45**: 408-418 [PMID: 23127799 DOI: 10.1016/j.biocel.2012.10.014]
- 29 **Dong X,** Ye X, Chen X, Chen T, Xie S, Li Q, Lin X, Huang Z. Intestinal and peripheral fibrinogen-like protein 2 expression in inflammatory bowel disease. *Dig Dis Sci* 2014; **59**: 769-777 [PMID: 24287641 DOI: 10.1007/s10620-013-2962-9]

**P- Reviewer:** Cordero OJ, Cordero PU, Yankee T   **S- Editor:** Qi Y  
**L- Editor:** A   **E- Editor:** Zhang FF





Published by **Baishideng Publishing Group Inc**  
7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA  
Telephone: +1-925-223-8242  
Fax: +1-925-223-8243  
E-mail: [bpgooffice@wjgnet.com](mailto:bpgooffice@wjgnet.com)  
Help Desk: <http://www.f6publishing.com/helpdesk>  
<http://www.wjgnet.com>



ISSN 1007-9327

